Eli Lilly is up 30.4% since the beginning of the year, and at $1,015 per share, it is trading close to its 52-week high of $1,110 from November 2025
Dahl D, Onishi Y, Norwood P et al (2022) Effect of subcutaneous tirzepatide vs placebo added to titrated Insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial
Novo Nordisk, maker of Ozempic, has stated that patient safety is a top priority and that it encourages independent research and will continue to work with regulatory bodies regarding the safety of GLP-1 medications
Considering dopamines pivotal role in the brains reward system, such alterations could lead to an imbalance in dopaminergic neurotransmission 43,44
Under their shearing action, proinsulin is converted into insulin and glucagon and secreted into blood
Elsevier Inc